Home Metabolism PGC-1α

PGC-1α

Choose Selective PGC-1α Inhibitors

PGC-1α Products

  • All (4)
  • PGC-1α Inhibitors (1)
  • PGC-1α Activators (3)
  • New PGC-1α Products
Catalog No. Product Name Information Product Use Citations Product Validations
S8528 SR-18292 SR-18292 inhibits PGC-1α gluconeogenic activity and reduces co-activation of HNF4α by modulating the interaction between GCN5 and PGC-1α.
Front Pharmacol, 2021, 12:624402
Cancers (Basel), 2020, 12(9)E2397
S1168 Valproic Acid (NSC 93819) sodium salt Valproic Acid sodium salt (NSC 93819, Sodium valproate) is a HDAC inhibitor by selectively inducing proteasomal degradation of HDAC2, used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches. Valproic acid induces Notch1 signaling in small cell lung cancer (SCLC) cells. Valproic acid is under investigation for treatment of HIV and various cancers. Valproic acid (VPA) induces autophagy and mitophagy by upregulation of BNIP3 and mitochondrial biogenesis by upregulating PGC-1α.
Pigment Cell Melanoma Res, 2021, 10.1111/pcmr.13014
Front Immunol, 2021, 12:771453
Front Oncol, 2021, 11:723966
S3944 Valproic acid (VPA) Valproic acid (VPA, 2-Propylvaleric Acid, Valproate) is a fatty acid with anticonvulsant properties used in the treatment of epilepsy. It is also a histone deacetylase (HDAC) inhibitor and is under investigation for treatment of HIV and various cancers. Valproic acid (VPA) induces autophagy and mitophagy by upregulation of BNIP3 and mitochondrial biogenesis by upregulating PGC-1α. Valproic acid activates Notch-1 signaling.
Front Immunol, 2021, 12:771453
Sci China Life Sci, 2021, 10.1007/s11427-020-1855-4
Anticancer Res, 2021, 41(2):687-697
S7447 ZLN005 ZLN005 is a potent and tissue-specific PGC-1α transcriptional activator.
Biomed Pharmacother, 2021, 144:112331
J Mol Neurosci, 2021, 10.1007/s12031-020-01775-6
Stem Cell Reports, 2020, S2213-6711(20)30418-5
S8528 SR-18292 SR-18292 inhibits PGC-1α gluconeogenic activity and reduces co-activation of HNF4α by modulating the interaction between GCN5 and PGC-1α.
Front Pharmacol, 2021, 12:624402
Cancers (Basel), 2020, 12(9)E2397
S1168 Valproic Acid (NSC 93819) sodium salt Valproic Acid sodium salt (NSC 93819, Sodium valproate) is a HDAC inhibitor by selectively inducing proteasomal degradation of HDAC2, used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches. Valproic acid induces Notch1 signaling in small cell lung cancer (SCLC) cells. Valproic acid is under investigation for treatment of HIV and various cancers. Valproic acid (VPA) induces autophagy and mitophagy by upregulation of BNIP3 and mitochondrial biogenesis by upregulating PGC-1α.
Pigment Cell Melanoma Res, 2021, 10.1111/pcmr.13014
Front Immunol, 2021, 12:771453
Front Oncol, 2021, 11:723966
S3944 Valproic acid (VPA) Valproic acid (VPA, 2-Propylvaleric Acid, Valproate) is a fatty acid with anticonvulsant properties used in the treatment of epilepsy. It is also a histone deacetylase (HDAC) inhibitor and is under investigation for treatment of HIV and various cancers. Valproic acid (VPA) induces autophagy and mitophagy by upregulation of BNIP3 and mitochondrial biogenesis by upregulating PGC-1α. Valproic acid activates Notch-1 signaling.
Front Immunol, 2021, 12:771453
Sci China Life Sci, 2021, 10.1007/s11427-020-1855-4
Anticancer Res, 2021, 41(2):687-697
S7447 ZLN005 ZLN005 is a potent and tissue-specific PGC-1α transcriptional activator.
Biomed Pharmacother, 2021, 144:112331
J Mol Neurosci, 2021, 10.1007/s12031-020-01775-6
Stem Cell Reports, 2020, S2213-6711(20)30418-5